Coeptis Therapeutics Holdings (COEP) Income from Continuing Operations (2021 - 2025)
Historic Income from Continuing Operations for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to -$2.9 million.
- Coeptis Therapeutics Holdings' Income from Continuing Operations fell 5849.64% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year decrease of 1759.55%. This contributed to the annual value of -$10.9 million for FY2024, which is 4885.2% up from last year.
- Coeptis Therapeutics Holdings' Income from Continuing Operations amounted to -$2.9 million in Q3 2025, which was down 5849.64% from -$4.3 million recorded in Q2 2025.
- Over the past 5 years, Coeptis Therapeutics Holdings' Income from Continuing Operations peaked at -$139650.0 during Q1 2021, and registered a low of -$19.2 million during Q1 2022.
- Over the past 5 years, Coeptis Therapeutics Holdings' median Income from Continuing Operations value was -$3.3 million (recorded in 2023), while the average stood at -$5.0 million.
- As far as peak fluctuations go, Coeptis Therapeutics Holdings' Income from Continuing Operations crashed by 1363411.6% in 2022, and later surged by 7120.04% in 2024.
- Quarter analysis of 5 years shows Coeptis Therapeutics Holdings' Income from Continuing Operations stood at -$139650.0 in 2021, then tumbled by 2007.4% to -$2.9 million in 2022, then fell by 27.61% to -$3.8 million in 2023, then increased by 19.81% to -$3.0 million in 2024, then increased by 3.75% to -$2.9 million in 2025.
- Its Income from Continuing Operations was -$2.9 million in Q3 2025, compared to -$4.3 million in Q2 2025 and -$3.4 million in Q1 2025.